Pink Park City fundraiser for cancer research shifts from the slopes to a virtual format parkrecord.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from parkrecord.com Daily Mail and Mail on Sunday newspapers.
People with cancer are at increased risk of illness and death from the COVID-19 virus. Huntsman Cancer Institute is among many cancer centers and organizations nationwide urging government leaders and health departments to prioritize access to COVID-19 vaccines for people with cancer and survivors of cancer.
Local deputy prosecutor retiring next month
Updated at
Share This
Zach Parris, left, with his wife, Tami. | Photo courtesy Tami Parris
POCATELLO – After a 20-year career with Bannock County, Deputy Prosecutor Zach Parris is officially retiring on March 2nd. He says he’s stepping down for health reasons.
“I want to take advantage of the time that I have and try to spend it with my family and enjoy my last few years. We’ll see how it works out,” Parris says in an interview with KPVI.
Parris was diagnosed with prostate cancer in 2012.
Despite ongoing treatment, Parris tells EastIdahoNews.com the cancer is under control and he’s feeling great.
Cabozantinib Effective in Treating Metastatic Kidney Cancer by Angela Mohan on February 15, 2021 at 3:21 PM
Cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer, as per results of a SWOG Cancer Research Network trial.
These findings will be presented at ASCO s virtual 2021 Genitourinary Cancers Symposium 2021. The findings will be simultaneously published in
The Lancet.
There are currently no effective treatments for metastatic papillary kidney cancer, or metastatic pRCC, a rare subtype of kidney cancer. One study of 38 patients found that the average survival rate was eight months after diagnosis.
Sumanta Pal, MD, clinical professor of medical oncology at City of Hope, a comprehensive cancer center, and an investigator at SWOG, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), said there is hope for metastatic papillary kidney cance
Study reveals cabozantinib most effective treatment for metastatic papillary kidney cancer ANI | Updated: Feb 14, 2021 11:12 IST
Washington [US], February 14 (ANI): In a SWOG Cancer Research Network trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer - findings expected to change medical practice.
These findings were published in The Lancet.
There are currently no effective treatments for metastatic papillary kidney cancer, or metastatic pRCC, a rare subtype of kidney cancer. One study of 38 patients found that the average survival rate was eight months after diagnosis.